Publication date: 29 September 2026 | Event date: 28 September 2026
The US Food and Drug Administration has approved Emcitate (tiratricol) for peripheral thyrotoxicosis in adults and children with monocarboxylate transporter 8 (MCT8) deficiency. It is the first FDA-approved treatment for this ultra-rare inherited disorder.
At a Glance
- First FDA-approved therapy for peripheral thyrotoxicosis caused by MCT8 deficiency.
- The approval was announced on 28 September 2026.
- The medicine is not a substitute for specialist endocrine and neurological care.
- US approval does not automatically establish Indian marketing authorisation or availability.
What is new?
MCT8 deficiency, also called Allan–Herndon–Dudley syndrome, impairs thyroid-hormone transport and can cause severe neurodevelopmental disability with peripheral thyrotoxicosis. Tiratricol is a thyroid-hormone analogue used to reduce harmful peripheral thyroid-hormone effects.
What this means for clinicians and families
The approval creates a regulated treatment option in the United States. Diagnosis, initiation, titration and biochemical monitoring require an experienced multidisciplinary team. Feeding-tube administration may be relevant for some patients.
Verified safety points
Reported adverse effects include diarrhoea, vomiting, rash and sweating. Concomitant thyroid medicines and changes in thyroid-function tests require specialist review. The US prescribing information should be used for dosing and monitoring.
What is known
Regulatory review considered clinical-study and long-term evidence in this rare disease. The approved indication is control of peripheral thyrotoxicosis; the degree to which treatment changes established neurological disability remains a separate clinical question.
Limitations and uncertainties
Rare-disease datasets are small, long-term outcomes continue to evolve, and individual responses vary. FDA orphan-drug database pages may update asynchronously; the approved US prescribing information is the controlling document.
India-specific caveat
No claim is made here that Emcitate is approved, marketed or routinely available in India. Clinicians should verify CDSCO status, lawful import pathways and institutional policy before any consideration of use.
Official sources
Related reading
New Drug & Drug Status updates on MedBodh
Last reviewed: 29 September 2026
Educational disclaimer: This article is for professional education and public information. It does not replace individual diagnosis, prescription, emergency assessment or local institutional protocol.